Dr. Paul Peter Tak, a physician, researcher, and biotech leader, emphasizes the importance of putting patients first in medical innovation, focusing on the need for better treatment options for early-stage prostate cancer. He discusses the challenges and importance of active surveillance in managing low-risk prostate cancer and calls for a more patient-centered approach to drug development. Dr. Tak emphasizes the need for innovative treatments that balance efficacy with quality of life considerations, especially for localized prostate cancer. He advocates for expanded research, diverse representation in clinical trials, and incorporating patient perspectives to improve outcomes and minimize side effects.
Source link
Prostate Cancer Management – We Need Better Options for Early-Stage Disease
